Trial Search Results

Natural History Study of Synucleinopathies

Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control of movement or cognition. Patients with synucleinopathies and signs of CNS-deficits are frequently diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA).

However, accumulation of alpha-synuclein and death of nerve cells can also begin outside the brain in the autonomic nerves. In such cases, syncucleinopathies present first with symptoms of autonomic impairment (unexplained constipation, urinary difficulties, and sexual dysfunction). In rare cases, hypotension on standing (a disorder known as orthostatic hypotension) may be the only clinical finding. This "pre-motor" autonomic stage suggests that the disease process may not yet have spread to the brain.

After a variable period of time, but usually within 5-years, most patients with abnormally low blood pressure on standing develop cognitive or motor abnormalities. This stepwise evolution indicates that the disease spreads from the body to the brain. Another indication of this spread is that acting out dreams (i.e., REM sleep behavior disorder, RBD) a problem that occurs when the lower part of the brain is affected, may also be the first noticeable sign of Parkinson disease.

The purpose of this study is to document the clinical features and biological markers of patients with synucleinopathies and better understand how these disorders evolve over time. The study will involve following patients diagnosed with a synucleinopathy (PD/DLB and MSA) and those believed to be in the "pre-motor" stage (with isolated autonomic impairment and/or RBD). Through a careful series of follow-up visits to participating Centers, we will focus on finding biological clues that predict which patients will develop motor/cognitive problems and which ones have the resilience to keep the disease at bay preventing spread to the brain. We will also define the natural history of MSA - the most aggressive of the synucleinopathies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

NYU Langone Health

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   1. Both male and female patients will be included

   2. Aged 18 or over

   3. Referred to any of the participating consortium sites with orthostatic intolerance,
   defined as symptoms of dizziness or lightheadedness in the standing position that
   disappear when supine.

Exclusion Criteria:

   1. Diabetes according to the American Diabetes Association criteria

   2. Congestive heart failure

   3. Lupus or other collagen vascular disease

   4. Systemic illness thought to be responsible for the orthostatic intolerance

   5. Drug-induced orthostatic hypotension (i.e., the use of alpha-blockers, diuretics,
   tricyclic antidepressants or others thought by the investigator to play an important
   role in the patient's orthostatic hypotension)

   6. Isolated vasovagal syncope

   7. Inability to comply with the protocol, e.g. uncooperative attitude, inability to
   return for follow-up visits, and unlikelihood of completing the study.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting